Zacks Investment Research Upgrades Vision-Sciences Inc. (CGNT) to “Hold”

Vision-Sciences Inc. (NASDAQ:CGNT) was upgraded by Zacks Investment Research from a “sell” rating to a “hold” rating in a research note issued on Tuesday.

According to Zacks, “Cogentix Medical, Inc. is a medical device company which designs, develops, manufactures and markets proprietary technologies serving the urology market. The company’s primary product consists of Urgent(R) PC Neuromodulation System and EndoSheath System. It operates primarily in Orangeburg, New York, The Netherlands and the United Kingdom. Cogentix Medical, Inc., formerly known as Vision-Sciences Inc., is headquartered in Orangeburg, New York. “

Separately, Roth Capital upgraded Vision-Sciences from a “neutral” rating to a “buy” rating in a research report on Wednesday, September 7th.

Vision-Sciences (NASDAQ:CGNT) opened at 1.75 on Tuesday. Vision-Sciences has a 12-month low of $0.71 and a 12-month high of $1.99. The company’s market cap is $45.75 million. The company has a 50-day moving average price of $1.52 and a 200 day moving average price of $1.15.

Vision-Sciences (NASDAQ:CGNT) last posted its quarterly earnings results on Tuesday, August 2nd. The medical device company reported ($0.10) EPS for the quarter, missing analysts’ consensus estimates of $0.01 by $0.11. Vision-Sciences had a negative return on equity of 27.43% and a negative net margin of 13.99%. On average, analysts forecast that Vision-Sciences will post ($0.21) EPS for the current fiscal year.

An institutional investor recently raised its position in Vision-Sciences stock. Amici Capital LLC boosted its position in Vision-Sciences Inc. (NASDAQ:CGNT) by 14.6% during the first quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 1,415,589 shares of the medical device company’s stock after buying an additional 180,689 shares during the period. Amici Capital LLC owned about 5.58% of Vision-Sciences worth $1,557,000 at the end of the most recent quarter. 30.43% of the stock is currently owned by institutional investors and hedge funds.

Vision-Sciences Company Profile

Cogentix Medical, Inc, formerly Vision-Sciences, Inc, is a medical device company. The Company designs, develops, manufactures and markets products for endoscopy with its product lines featuring a visualization system and sterile disposable microbial barrier, EndoSheath technology. The Company produces and markets Endoscopes, such as cystoscopes, ureteroscopes, laryngoscopes, otoscopes, sinuscopes, trans-nasal esophagoscopy (TNE) and bronchoscopes for medical use and borescopes for industrial use, and digital processing units (DPU).

5 Day Chart for NASDAQ:CGNT

Get a free copy of the Zacks research report on Vision-Sciences (CGNT)

For more information about research offerings from Zacks Investment Research, visit

Receive News & Ratings for Vision-Sciences Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Vision-Sciences Inc. and related companies with's FREE daily email newsletter.

Leave a Reply

© 2006-2016 Mideast Time.